Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

The latest HPRA inspection in February 2025 was highly successful-both QC licences were renewed, and viral vector manufacturing was added to the MIA (IMP) licence. This means the Shannon site can ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fractyl Health, Inc. Common Stock misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.44. Operator: Good afternoon, and ...

Under Japan’s compulsory insurance system, all residents are legally obligated to be ... possibly reflecting the superior tolerability and convenient dosing schedules of these incretin-based agents.

Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide.

The company will also receive the first readout from the retatrutide program, a triple-acting injectable incretin being studied in overweight patients with osteoarthritis of the knee, which could ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Now, Shen et al. have developed a system to improve intranasal delivery by harnessing the commensal bacterium, Lactobacillus plantarum (Lp). In mouse models of obesity, intranasal administration ...

Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug ...

Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of action that it hopes to acquire via a $1.93 billion takeover of ...